Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21/CDK4/6/Cyclin D1 axis driving tumorigenesis and drug resistance.
X. Cheng, Y. Sun, M. Highkin, N. Vemalapally, X. Jin, B. Zhou, J. L. Prior, A. R. Tipton, S. Li, A. Iliuk, S. Achilefu, I. S. Hagemann, J. R. Edwards, R. Bose
This study investigates how HER2 V777L and PIK3CA H1047R mutations drive breast cancer tumorigenesis and drug resistance, showing effective combination therapies.
bioRxiv · Nov 9, 2022 · PreprintCancer Biology